Guidelines group therapy choices into 2 patient groups:
PD-L1 ≥50%
Single-agent immunotherapy or immunotherapy + chemotherapy
PD-L1 <50%
Immunotherapy + chemotherapy
PROphet® stratifies therapy choices into
6 patient groups:
PD-L1 ≥50% + PROphet® POSITIVE: Single-agent
PD-1/PD-L1 inhibitor
PD-L1 ≥50% + PROphet® NEGATIVE: Combination
PD-1/PD-L1 inhibitor + chemotherapy
PD-L1 1-49% + PROphet® POSITIVE: Combination
PD-1/PD-L1 inhibitor + chemotherapy (preferred)
PD-L1 1-49% + PROphet® NEGATIVE: Low to moderate benefit with PD-1/PD-L1 inhibitor + chemotherapy
PD-L1 <1% + PROphet® POSITIVE: Combination
PD-1/PD-L1 inhibitor + chemotherapy
PD-L1 <1% + PROphet® NEGATIVE: Poor outcome on PD-1/PD-L1 inhibitor with or without chemotherapy. Consider alternative guideline-approved therapies or first-line clinical trial
What is the PROphetNSCLC™ test?
PROphet® NSCLC guides first-line PD-1/PD-L1 inhibitor treatment decisions for metastatic NSCLC patients by accurately predicting likelihood of clinical benefit and overall survival when administered as a single agent vs. in combination with chemotherapy.
How was PROphetNSCLC™ validated?
The PROphet® model was developed based on clinical, demographic, and proteomic data of over 600 patients within the framework of an ongoing clinical study conducted by OncoHost (PROPHETIC; NCT04056247). To date, the trial has over 1,700 patients recruited across 40 sites worldwide, making it one of the largest prospective cohorts in the precision oncology field.
Plasma was isolated from the blood and profiled via the SomaScan® Discovery Assay v4.1[2-3], and the resulting proteomic profiles were analyzed in conjunction with patient clinical data. The clinical benefit prediction algorithm was developed to identify patients who are more likely to benefit from PD-1/PD-L1 inhibitor treatment. Patient clinical benefit probability is predicted and linearly transformed to a PROphet® Score between 0 to 10.
The PROphetNSCLC™ test is supported by a blinded validation demonstrating that it accurately predicts a patient’s clinical benefit and associated overall survival differences with single-agent versus combination treatment plans.
View all our clinical evidence here.
How does PROphetNSCLC™ differ from other NGS testing/comprehensive profiling?
Proteomics and next-generation sequencing (NGS) are complementary approaches in understanding cancer dynamics. PROphetNSCLC™ focuses on proteomic pattern analysis, revealing biomarkers that indicate biological processes within the tumor and the body, influencing treatment success.
On the other hand, NGS examines the genomic and genetic makeup of the tumor, identifying crucial genetic alterations which guide your overall treatment planning. Integrating proteomic analysis with NGS can provide you with valuable insights into your patient’s tumor growth, characteristics, and predicted response to treatment.
Why is proteomics valuable in determining immunotherapy resistance?
While immunotherapy has shown remarkable success in some cases, not all patients respond equally, and resistance to treatment can be a significant challenge.
Proteomics provides insights into the complex interactions between the immune system and cancer cells at a molecular level. By analyzing protein expression patterns, we can identify biomarkers that predict patient response to immunotherapy.
Proteomics also provides insights into the tumor microenvironment, revealing crucial interactions between cancer and immune cells. The tumor microenvironment plays a vital role in influencing the effectiveness of immunotherapy, and proteomics can provide information about the types and quantities of immune cells present, as well as the signaling molecules and proteins secreted by both cancer and immune cells. Understanding these interactions can help reveal mechanisms of resistance and suggest ways to overcome them.
By leveraging proteomic insights, we can tailor treatments based on individual patient profiles, leading to more effective and personalized cancer care and, ultimately, improving patient outcomes.
How is the patient’s blood drawn for PROphetNSCLC™?
OncoHost will send a mobile phlebotomist to draw one pre-treatment blood test from the comfort of the patient’s home or at the patient’s preferred location. OncoHost will be in touch with the patient directly to coordinate the appointment.
Does OncoHost provide in-clinic blood draws?
Yes. Contact our Client Services team to coordinate this option for your clinic: contact@oncohost.com or 1-855-950-2112.
How much plasma is required for the test?
0.2 microliters.
What is the patient eligibility criteria to order the PROphetNSCLC™ test?
The PROphetNSCLC™ test is intended for use in patients who meet the following criteria:
- Age 18 and above
- ECOG (Eastern Cooperative Oncology Group) performance status of 0-2
- Normal hematologic, renal, and liver functions
- Newly diagnosed stage IV non-small cell lung cancer (NSCLC)
- First-line setting
Does OncoHost also provide PD-L1 test results?
No, PD-L1 testing should be completed using your regular provider. PROphet® NSCLC is ordered at the same time as NGS and PD-L1 so that all results are available to you at the time of treatment planning.
Combining the PROphet® NSCLC test results with the PD-L1 score provides additional information on the patient’s expected response, which may support the choice of first-line therapy and affect the patient over time.
PROphet® NSCLC predicts differential overall survival (OS) and progression-free survival (PFS) outcomes when combined with PD-L1 expression level.
What if the patient’s report shows a PROphet® NEGATIVE result?
This will provide you with valuable insights into your patient’s first-line treatment plan, offering treatment considerations for therapies they are likely to respond to based on their personalized proteomic analysis.
What if the patient’s report shows a PROphet® POSITIVE result?
This means that the patient has a high likelihood of achieving clinical benefit on an approved PD-1/PD-L1 inhibitor immunotherapy regimen.
How do I order the PROphetNSCLC™ test for my patient?
Online ordering: Order online by logging in or signing up for a physician portal account here.
Fax ordering: Download our test requisition form (TRF) here and fax it completed to 1-919-415-1308.
How will my patients be billed for PROphetNSCLC™?
In effect until December 31, 2024
*OncoHost’s Financial Assistance Program is only available to patients whose tests were ordered within the United States and U.S. territories.
What is the test turnaround time?
Results are available within 8 days from sample receipt at OncoHost's CLIA lab.
Is your lab CLIA Certified and COLA Accredited?
Yes. Please find our laboratory’s licensing certificates and permits here.
What are OncoHost’s current available PROphet® test indications? What’s in the pipeline?
The PROphet® NSCLC test is currently available to order in every US state except for New York (pending).
In the pipeline:
I’m interested in signing my practice up for OncoHost’s physician portal/ordering a test. Who do I contact?
To learn more about signing your practice up for OncoHost’s physician portal or ordering a test, please contact your Regional Sales Director, or reach out to our Client Services team at contact@oncohost.com or 1-855-950-2112.
I’m having trouble logging in to my physician portal account – who do I contact for help?
For issues related to OncoHost physician portal accounts, please email contact@oncohost.com.
I need to reset my portal password. Who do I contact?
For any portal password-related issues, please contact our Client Services team contact@oncohost.com or call 1-855-950-2112 during business hours (Mon-Fri, 8:00am-5:00pm).
